Advanced Lung Cancer Clinical Trial
Official title:
Change in Neutrophil to Lymphocyte Ratio (NLR) and Survival Among Advanced Lung Cancer Patients Receiving Immune Checkpoint Inhibitors With Immunomodulator: a Retrospective Study
The main objective of this study is to evaluate the change of neutrophil to lymphocyte ratio (NLR) after 6-week treatment of immune checkpoint inhibitors (ICIs) with or without immunomodulatory drugs and recognize the effect of post-treatment NLR and overall survival in advanced lung cancer patients by retrospective review.
In recent years, the therapeutic strategies for lung cancer have been enriched with small molecular targeted therapy and immunotherapy. In this retrospective study, we will observe the change in NLR and explore its possible association with survival among advanced lung cancer patients receiving Immune checkpoint inhibitors (ICIs) with and without such immuno-modulator, Astragalus Polysaccharide Injection. It can be used to understand the relationship between NLR values and the survival rate of lung cancer patients after ICIs treatment. Physicians can refer to this result to give patients the suitable treatment recommendations. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04575831 -
Exercise, Nutrition, and Palliative Care in Advanced Lung Cancer (ENPAL)
|
N/A | |
| Completed |
NCT04069494 -
Descriptors and Predictors of Burden and Information Needs
|
||
| Terminated |
NCT03330834 -
CAR-T Cell Immunotherapy for Advanced Lung Cancer
|
Phase 1 | |
| Withdrawn |
NCT03004105 -
MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
| Withdrawn |
NCT03501056 -
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05279521 -
The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer.
|
N/A | |
| Terminated |
NCT02768337 -
Cambridge Brain Mets Trial 1
|
Phase 1/Phase 2 | |
| Completed |
NCT04672369 -
A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC
|
Phase 1 | |
| Recruiting |
NCT03751592 -
Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05431569 -
A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06456138 -
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06228209 -
Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer
|
N/A | |
| Completed |
NCT04672356 -
A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT04670445 -
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
|
N/A | |
| Not yet recruiting |
NCT06107894 -
TIL Therapy for Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06183762 -
A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer
|
||
| Recruiting |
NCT05664971 -
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05815862 -
Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer
|
Phase 2 | |
| Recruiting |
NCT05805956 -
IMM2902 in Patients With Advanced Solid Tumors Expressing HER2
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06106152 -
WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody
|
Early Phase 1 |